Lymphocytic leiomyositis and myenteric ganglionitis are intrinsic features of cystic fibrosis: Studies in distal intestinal obstruction syndrome and meconium ileus

Journal of Pediatric Gastroenterology and Nutrition

Volumn 49, Issue 1, 2009, Pages 42-51

  Smith, Virpi V ^a   Schäppi, Michela G ^b   Bisset, W Michael ^c   Kiparissi, Fevronia ^a   Jaffe, Adam ^d   Milla, Peter J ^a   Lindley, Keith J ^a,e  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c ROYAL ABERDEEN CHILDREN S HOSPITAL   (United Kingdom)

^d SYDNEY CHILDREN'S HOSPITAL   (Australia)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cystic fibrosis; Distal ileal obstruction syndrome; Ganglionitis; Inflammation; Meconium ileus

Indexed keywords

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COLON DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISTAL ILEAL OBSTRUCTION SYNDROME; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILEITIS; IMMUNOHISTOCHEMISTRY; INFANT; LYMPHOCYTIC GANGLIONITIS; MALE; MANOMETRY; MECONIUM ILEUS; MYENTERIC PLEXUS; NEUROPATHOLOGY; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SMALL INTESTINE OBSTRUCTION; STAINING;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; CYSTIC FIBROSIS; DUODENUM; FEMALE; FIBROBLASTS; GANGLION CYSTS; HUMANS; ILEUM; ILEUS; INFANT; INFLAMMATION; INTESTINAL ATRESIA; INTESTINAL MUCOSA; INTESTINAL PSEUDO-OBSTRUCTION; LYMPHOCYTES; MALE; MANOMETRY; MECONIUM; MUSCLE CELLS; MYENTERIC PLEXUS; RETROSPECTIVE STUDIES;

EID: 67650697678     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318186d35a     Document Type: Article

References (62)

1. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-73.
2. Zielenski J, Rozmahel R, Bozon D, et al. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1991;10:214-28.
3. www.genet.sickkids.on.ca/cftr.
4. Kunzelmann K. CFTR: interacting with everything. News Physiol Sci 2001;16:167-70.
5. Kelley TJ, Elmer HL, Corey DA. Reduced Smad3 protein expression and altered transforming growth factor-beta1-mediated signaling in cystic fibrosis epithelial cells. Am J Respir Cell Mol Biol 2001;25:732-8.
6. Soltys J, Bonfield T, Chmiel J, et al. Functional IL-10 deficiency in the lung of cystic fibrosis (cftr(-/-)) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar macrophages. J Immunol 2002;168:1903-10.
7. Tirouvanziam R, Khazaal I, Peault B. Primary inflammation in human cystic fibrosis small airways. Am J Physiol Lung Cell Mol Physiol 2002;283:L445-51.
8. Weber AJ, Soong G, Bryan R, et al. Activation of NF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Cl-channel function. Am J Physiol Lung Cell Mol Physiol 2001; 281:L71-8.
9. Raia V, Maiuri L, de Ritis G, et al. Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients. Pediatr Res 2000;47:344-50.
10. Rosenstein BJ, Langbaum TS. Incidence of distal intestinal obstruction syndrome in cystic fibrosis. J Pediatr Gastroenterol Nutr 1983;2:299-301.
11. Kerem E, Corey M, Kerem B, et al. Clinical and genetic comparisons of patients with cystic fibrosis, with or without meconium ileus. J Pediatr 1989;114:767-73.
12. Murshed R, Spitz L, Kiely E, et al. Meconium ileus: a ten-year review of thirty-six patients. Eur J Pediatr Surg 1997;7:275-7.
13. Mushtaq I, Wright VM, Drake DP, et al. Meconium ileus secondary to cystic fibrosis. The East London experience. Pediatr Surg Int 1998;13:365-9.
14. Millar-Jones L, Goodchild MC. Cystic fibrosis, pancreatic sufficiency and distal intestinal obstruction syndrome: a report of four cases. Acta Paediatr 1995;84:577-8.
15. Ahmed N, Corey M, Forstner G, et al. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut 2003;52:1159-64.
16. Ojeda VJ, Levitt S, Ryan G, et al. Cystic fibrosis, Crohn's colitis, and adult meconium ileus equivalent. Dis Colon Rectum 1986;29:567-71.
17. Smyth RL, Ashby D, O'Hea U, et al. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet 1995; 346:1247-51.
18. Fell JM, Smith VV, Milla PJ. Infantile chronic idiopathic intestinal pseudo-obstruction: the role of small intestinal manometry as a diagnostic tool and prognostic indicator. Gut 1996;39:306-11.
19. Ruuska TH, Karikoski R, Smith VV, et al. Acquired myopathic intestinal pseudo-obstruction may be due to autoimmune enteric leiomyositis. Gastroenterology 2002;122:1133-9.
20. Smith VV, Gregson N, Foggensteiner L, et al. Acquired intestinal aganglionosis and circulating autoantibodies without neoplasia or other neural involvement. Gastroenterology 1997;112:1366-71.
21. Mascarenhas MR. Treatment of gastrointestinal problems in cystic fibrosis. Curr Treat Options Gastroenterol 2003;6:427-41.
22. Cleghorn GJ, Stringer DA, Forstner GG, et al. Treatment of distal intestinal obstruction syndrome in cystic fibrosis with a balanced intestinal lavage solution. Lancet 1986;1:8-11.
23. Rubinstein S, Moss R, Lewiston N. Constipation and meconium ileus equivalent in patients with cystic fibrosis. Pediatrics 1986; 78:473-9.
24. Davidson AC, Harrison K, Steinfort CL, et al. Distal intestinal obstruction syndrome in cystic fibrosis treated by oral intestinal lavage, and a case of recurrent obstruction despite normal pancreatic function. Thorax 1987;42:538-41.
25. Feingold J, Guilloud-Bataille M. Genetic comparisons of patients with cystic fibrosis with or without meconium ileus. Clinical Centers of the French CF Registry. Ann Genet 1999;42:147-50.
26. Lloyd-Still JD. Crohn's disease and cystic fibrosis. Dig Dis Sci 1994;39:880-5.
27. Tornblom H, Lindberg G, Nyberg B, et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002;123:1972-9.
28. Schappi MG, Smith VV, Milla PJ, et al. Eosinophilic myenteric ganglionitis is associated with functional intestinal obstruction. Gut 2003;52:752-5.
29. Schappi MG, Roulet M, Rochat T, et al. Electrogastrography reveals post-prandial gastric dysmotility in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2004;39:253-6.
30. Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 1999;277 (2 Pt 1):C183-201.
31. Pucilowska JB, McNaughton KK, Mohapatra NK, et al. IGF-I and procollagen alpha1(I) are coexpressed in a subset of mesenchymal cells in active Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2000;279:G1307-22.
32. Pucilowska JB, Williams KL, Lund PK. Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 2000;279:G653-9.
33. Matthes H, Herbst H, Schuppan D, et al. Cellular localization of procollagen gene transcripts in inflammatory bowel diseases. Gastroenterology 1992;102:431-42.
34. Schroeder TH, Lee MM, Yacono PW, et al. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc Natl Acad Sci U S A 2002;99:6907-12.
35. Pier GB. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. Proc Natl Acad Sci U S A 2000;97:8822-8.
36. van Tol EA, Holt L, Li FL, et al. Bacterial cell wall polymers promote intestinal fibrosis by direct stimulation of myofibroblasts. Am J Physiol 1999;277 (1 Pt 1): G245-55.
37. Di Mari JF, Mifflin RC, Adegboyega PA, et al. IL-1alpha-induced COX-2 expression in human intestinal myofibroblasts is dependent on a PKCzeta-ROS pathway. Gastroenterology 2003;124:1855-65.
38. Lu G, Qian X, Berezin I, et al. Inflammation modulates in vitro colonic myoelectric and contractile activity and interstitial cells of Cajal. Am J Physiol 1997;273 (6 Pt 1): G1233-45.
39. Serban DE, Florescu P, Miu N. Fibrosing colonopathy revealing cystic fibrosis in a neonate before any pancreatic enzyme supplementation. J Pediatr Gastroenterol Nutr 2002;35:356-9.
40. Smyth RL, van Velzen D, Smyth AR, et al. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994;343:85-6.
41. Pawel BR, de Chadarevian JP, Franco ME. The pathology of fibrosing colonopathy of cystic fibrosis: a study of 12 cases and review of the literature. Hum Pathol 1997;28:395-9.
42. Pettei MJ, Leonidas JC, Levine JJ, et al. Pancolonic disease in cystic fibrosis and high-dose pancreatic enzyme therapy. J Pediatr 1994;125:587-9.
43. Campbell CA, Forrest J, Musgrove C. High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis. Lancet 1994;343:109-10.
44. Prestridge L, Rogers BB, Pritchard M, et al. Diffuse fibrosis of the colon complicating cystic fibrosis. J Pediatr Gastroenterol Nutr 1996;22:219-24.
45. Jones R, Franklin K, Spicer R, et al. Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes. Lancet 1995;346:499.
46. Dodge JA. Concern about records of fibrosing colonopathy study. Lancet 2001;357:1526-7.
47. Dodge JA. Further comments on fibrosing colonopathy study. Lancet 2001;358:1546.
48. Powell CJ. Colonic toxicity from pancreatins: a contemporary safety issue. Lancet 1999;353:911-5.
49. Bakowski M. Pancreatic enzymes and fibrosing colonopathy. Lancet 1999;354:249.
50. FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997;336:1283-9.
51. Prescott P. Pancreatic enzymes and fibrosing colonopathy. Lancet 1999;354:250.
52. Lloyd-Still JD, Beno DW, Uhing MR, et al. Pancreatic enzymes and fibrosing colonopathy. Lancet 1999;354:251.
53. Freiman JP, FitzSimmons SC. Colonic strictures in patients with cystic fibrosis: results of a survey of 114 cystic fibrosis care centers in the United States. J Pediatr Gastroenterol Nutr 1996;22:153-6.
54. Littlewood JM, Wolfe SP. Control of malabsorption in cystic fibrosis. Paediatr Drugs 2000;2:205-22.
55. van Velzen D. Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes. Lancet 1995;346:499-500.
56. Dialer I, Hundt C, Bertele-Harms RM, et al. Sonographic evaluation of bowel wall thickness in patients with cystic fibrosis. J Clin Gastroenterol 2003;37:55-60.
57. Simon-Bouy B, Satre V, Ferec C, et al. Hyperechogenic fetal bowel: a large French collaborative study of 682 cases. Am J Med Genet 2003;121A:209-13.
58. Ramsden WH, Moya EF, Littlewood JM. Colonic wall thickness, pancreatic enzyme dose and type of preparation in cystic fibrosis. Arch Dis Child 1998;79:339-43.
59. Orgad S, Berkenstadt M, Achiron R, et al. Hyperechogenic bowel loops and meconium ileus in a fetus carrying the D1152H and G542X cystic fibrosis CFTR mutations. Prenat Diagn 2002;22: 636-7.
60. Mazziotti MV, Langer JC. Laparoscopic full-thickness intestinal biopsies in children. J Pediatr Gastroenterol Nutr 2001;33:54-7.
61. Koletzko S, Stringer DA, Cleghorn GJ, et al. Lavage treatment of distal intestinal obstruction syndrome in children with cystic fibrosis. Pediatrics 1989;83:727-33.
62. Koletzko S, Corey M, Ellis L, et al. Effects of cisapride in patients with cystic fibrosis and distal intestinal obstruction syndrome. J Pediatr 1990;117:815-22.